Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment

HURST, L. A., BUNNING, R. A. D., COURAUD, P.-O., ROMERO, I. A., WEKSLER, B. B., SHARRACK, B. and WOODROOFE, M. N. (2009). Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. Journal of neuroimmunology, 210 (1-2), 108-112.

Full text not available from this repository.
Link to published version:: https://doi.org/10.1016/j.jneuroim.2009.02.008

Abstract

ADAM-17 expression is localised to endothelial cells in the human central nervous system (CNS) and is increased in multiple sclerosis (MS) white matter, suggesting a role in MS pathogenesis. Expression of ADAM-17, TIMP-3, and fractalkine were investigated in a human brain endothelial cell line (hCMEC/D3) after pro-inflammatory cytokine treatment. Tumour necrosis factor (TNF) significantly increased fractalkine mRNA (> 100 fold) and protein expression, which was associated with increased shedding of fractalkine from the cell. Fractalkine shedding may regulate immune cell trafficking into the CNS, however, this does not appear to be directly controlled by ADAM-17 activity.

Item Type: Article
Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomedical Research Centre
Identification Number: https://doi.org/10.1016/j.jneuroim.2009.02.008
Page Range: 108-112
Depositing User: Users 4 not found.
Date Deposited: 12 May 2010 09:31
Last Modified: 18 Mar 2021 21:15
URI: https://shura.shu.ac.uk/id/eprint/1874

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics